
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : KVA12.1
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Kineta
Deal Size : Undisclosed
Deal Type : Partnership
Humedix Closes Strategic Investment in US-based Kineta to Boost CMO Business
Details : Humedix has secured certain exclusive distribution rights in Korea for products that are commercialized from Kineta's pipeline currently under development including KVA12.1.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
October 04, 2021
Lead Product(s) : KVA12.1
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Kineta
Deal Size : Undisclosed
Deal Type : Partnership
